PREDICTIVE™ - A global, prospective observational study to evaluate insulin detemir treatment in types 1 and 2 diabetes: Baseline characteristics and predictors of hypoglycaemia from the European cohort

Diabetes, Obesity and Metabolism

Volumn 9, Issue 3, 2007, Pages 428-434

  Luddeke H J ^a   Sreenan, S ^b   Aczel, S ^c   Maxeiner, S ^d   Yenigun, M ^e   Kozlovski, P ^f   Gydesen, H ^f   Dornhorst, A ^g  

^a Praxis Lüddeke Trauner   (Germany)

^b Royal College of Surgeons in Ireland   (Ireland)

^c Landeskrankenhaus Feldkirch   (Austria)

^d Schwerpunktpraxis Bosenheim   (Germany)

^e HASEKI EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^f NOVO NORDISK A S   (Denmark)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Diabetes; Diabetes treatment; Glycaemic control; Insulin analogue; Insulin therapy

Indexed keywords

HEMOGLOBIN A1C; INSULIN DETEMIR; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLYCOSYLATED HEMOGLOBIN; INSULIN;

ADULT; AGED; ANALYSIS OF COVARIANCE; ARTICLE; BODY MASS; BODY WEIGHT; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; EUROPE; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; METHODOLOGY; NON INSULIN DEPENDENT DIABETES MELLITUS; CHEMICALLY INDUCED DISORDER; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; MIDDLE AGED; PHYSIOLOGY; PROSPECTIVE STUDY; SEX DIFFERENCE; TREATMENT OUTCOME;

ADULT; BLOOD GLUCOSE; BODY MASS INDEX; BODY WEIGHT; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEX FACTORS; TREATMENT OUTCOME;

EID: 33947704161     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2006.00677.x     Document Type: Article

References (18)

1. DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
3. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
4. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000; 321: 405-412.
5. Stratton IM, Cull CA, Adler AI, Matthews DR, Neil HA, Holman RR. Additive effects of glycaemia and blood pressure exposure on risk of complications in type 2 diabetes: A prospective observational study (UKPDS 75). Diabetologia 2006; 49: 1761-1769.
6. DCCT Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes 1997; 46: 271-286.
7. Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: Results from the DCCT. Diabetes Control and Complications Trial. JAMA 1998; 280: 140-146.
8. Farmer A, Kinmonth AL, Suton S. Measuring beliefs about taking hypoglycaemic medication among people with Type 2 diabetes. Diabet Med 2006; 23: 265-270.
9. Ridderstrale M, Gudbjornsdottir S, Eliasoon B, Nilsson PM, Cederholm J, Steering Committee of the Swedish National Diabetes Register (NDR). Obesity and cardiovascular risk factors in type 2 diabetes: Results from the Swedish National Diabetes Register. J Intern Med 2006; 259: 314-322.
10. Levemir prescribing information. http://www.levemir-us.com/ prescribing_information.pdf. Accessed 26 April 2006.
11. Vague P, Selam JL, Skeie S et al. Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care 2003; 26: 590-596.
12. Hermansen K, Fontaine P, Kukolja K, Peterkova V, Leth G, Gall MA. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. Diabetologia 2004; 47: 622-629.
13. Russell-Jones D, Simpson R, Hylleberg B, Draeger E, Bolinder J. Effects of once-daily insulin detemir or NPH insulin on blood glucose control in patients with type 1 diabetes mellitus using a basal-bolus regimen. Clin Ther 2004; 26: 724-736.
14. Home P, Bartley P, Russell-Jones D et al. Insulin detemir offers improved glycemic control compared with NPH insulin in people with type 1 diabetes: A randomized clinical trial. Diabetes Care 2004; 27: 1081-1087.
15. RašlováK, Bohoev M, Raz I, Leth G, Gall MA, Hancu N. Insulin detemir and insulin aspart: A promising basal-bolus regimen for type 2 diabetes. Diabetes Res Clin Pract 2004; 66: 193-201.
16. Robertson KJ, Schoenle EM Gucev Z, Mordhorst L, Gall M-A, Ludvigsson J. Benefits of insulin detemir over NPH insulin in children and adolescents with type 1 diabetes: Lower and more predictable fasting plasma glucose and lower risk of nocturnal hypoglycemia. Diabet Med 2005; 22 (Suppl. 2): 45 (Abstract P66).
17. Home P, Kurtzhals P. Insulin detemir: From concept to clinical experience. Expert Opin Pharmacother 2006; 7: 325-343.
18. Murata HG, Duckworth WC, Shah JH, Wendel CS, Hoffman RM. Sources of glucose variability in insulin-treated type 2 diabetes: The Diabetes Outcomes in Veterans Study (DOVES). Clin Endocrinol (Oxf) 2004; 60: 451-456.